Hinge Health’s long-anticipated IPO is generating significant buzz as the first major digital health offering since Waystar’s debut in 2024, raising questions about whether the public markets will value Hinge at or near its prior $6.2 billion private valuation. While the company has shown impressive revenue growth to $390.4M in 2024 and improved margins, concerns remain about future growth beyond the saturated self-insured employer market and its ability to expand beyond musculoskeletal (MSK) care into adjacent areas like behavioral health or GI. As a leader in digital MSK, Hinge faces pressure to either build or buy capabilities in new clinical categories to meet employers’ growing demand for consolidated solutions.
Trending
- When GI Puts AI to Work Beyond Polyp Detection
- AI Model Detects Colorectal Cancer and Advanced Adenomas in Blood (Bioengineer)
- ACG: Anesthesia support, strategic integration of APPs needed to bolster GI workforce (Healio)
- Medicare adds specialty code for physician nutrition specialists (GI & Hepatology News)
- EnVision Endoscopy Announces Oversubscribed Series A Financing and Reaches First 50 Patient Procedures with SimpleStitch™ Suturing System (PR Newswire)
- GI centers can’t explain their cancellation spike (Becker’s GI & Endoscopy)
- Beyond Burnout: Recognizing and Reframing the Heartsink Response in Gastroenterologists and Hepatologists (Gastroenterology)
- AGA and AASLD Joint Guidelines on PBC Diagnosis and Management (Gastroenterology Advisor)
